E
Empyrean Neuroscience
Biotech & Life Sciences · New York City, United States · Founded 2019
Using genetic engineering to treat severe neuropsychiatric and neurologic illnesses in a way that will revolutionize healthcare MoreLess
Empyrean.bio is a pioneering biotechnology company focused on the genetic engineering of fungi and plants to develop neuroactive therapeutics. The company addresses the needs of patients suffering from debilitating neuropsychiatric and neurologic disorders such as depression, post-traumatic stress disorder (PTSD), substance abuse disorders, and chronic pain. By leveraging proprietary capabilities in fungi and plant genetics, bioinformatics, transformation, and regeneration, Empyrean.bio can upregulate and downregulate specific genes to modify the production of neuroactive compounds. This innovative approach allows for the creation of highly targeted treatments that can potentially transform the landscape of mental health and neurological care.
Empyrean.bio operates in the biotechnology and pharmaceutical markets, serving healthcare providers, research institutions, and patients. The company's business model revolves around the development and commercialization of its proprietary neuroactive compounds. Revenue is generated through partnerships, licensing agreements, and direct sales of its therapeutic products.
Keywords: genetic engineering, neuroactive therapeutics, fungi, plants, depression, PTSD, substance abuse, chronic pain, bioinformatics, biotechnology.
Company overview
Empyrean Neuroscience company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2019
- Headquarters
- New York City, United States
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 57.0
Valuation & funding
Empyrean Neuroscience funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Oct 2022 | $22M | $88M | Spore Partners | ↗ |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 8 |
| 2025 | 8 |
| 2024 | 8 |
| 2023 | 10 |
| 2022 | 10 |
Growth signals
Empyrean Neuroscience website traffic
Latest recorded traffic for Empyrean Neuroscience is 250 monthly website visits, up 108.3% over the last three months. Empyrean Neuroscience's team grew 0% over the past year.
Comparisons
Empyrean Neuroscience compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Empyrean Neuroscience's talent
Source: Dealroom Talent Intelligence.
Investors
1 investor on Empyrean Neuroscience's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Empyrean Neuroscience has talent and traffic
team presence
In the news
Latest news about Empyrean Neuroscience
Recent press, funding announcements, and product moves mentioning Empyrean Neuroscience — open to read from the original sources.
Market sentiment
What the market is saying about Empyrean Neuroscience
An AI-synthesized read of the highest-engagement posts about Empyrean Neuroscience on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Empyrean Neuroscience’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.